Antibodies against type I interferon: detection and association with severe clinical outcome in COVID‐19 patients - Université Paris Cité Accéder directement au contenu
Article Dans Une Revue Clinical and Translational Immunology Année : 2021

Antibodies against type I interferon: detection and association with severe clinical outcome in COVID‐19 patients

David Goncalves
Kahina Saker

Résumé

Objectives: Impairment of type I interferon (IFN-I) immunity has been reported in critically ill COVID-19 patients. This defect can be explained in a subset of patients by the presence of circulating autoantibodies (auto-Abs) against IFN-I. We set out to improve the detection and the quantification of IFN-I auto-Abs in a cohort of critically ill COVID-19 patients, in order to better evaluate the prevalence of these Abs as the pandemic progresses, and how they correlate with the clinical course of the disease. Methods: The concentration of anti-IFN-α2 Abs was determined in the serum of 84 critically ill COVID-19 patients who were admitted to ICU in Hospices Civils de Lyon, France, using a commercially available kit (Thermo Fisher, Catalog #BMS217). Results: A total of 21 of 84 (25%) critically ill COVID-19 patients had circulating anti-IFN-α2 Abs above cut-off (> 34 ng mL-1). Among them, 15 of 21 had Abs with neutralising activity against IFN-α2, that is 15 of 84 (18%) critically ill patients. In addition, we noticed an impairment of the IFN-I response in the majority of patients with neutralising anti-IFN-α2 Abs. There was no significant difference in the clinical characteristics or outcome of with or without neutralising anti-IFN-α2 auto-Abs. We detected anti-IFN-α2 auto-Abs in COVID-19 patients' sera throughout their ICU stay. Finally, we also found auto-Abs against multiple subtypes of IFN-I including IFN-ω. Conclusions: We reported that 18% of critically ill COVID-19 patients were positive for IFN-I auto-Abs, whereas all mild COVID-19 patients were negative, confirming that the presence of these antibodies is associated with a higher risk of developing a critical COVID-19 form.

Dates et versions

hal-03708112 , version 1 (29-06-2022)

Identifiants

Citer

David Goncalves, Mehdi Mezidi, Paul Bastard, Magali Perret, Kahina Saker, et al.. Antibodies against type I interferon: detection and association with severe clinical outcome in COVID‐19 patients. Clinical and Translational Immunology, 2021, 10 (8), ⟨10.1002/cti2.1327⟩. ⟨hal-03708112⟩
27 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More